Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of ($0.07), $0.07 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $48.1 million versus the consensus estimate of $47.07 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2024 revenue of $200-220 million, versus the consensus of $223.2 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.